# A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

> **NCT04612413** · PHASE2 · COMPLETED · sponsor: **Enlivex Therapeutics Ltd.** · enrollment: 148 (actual)

## Conditions studied

- Sepsis
- Community-acquired Pneumonia
- Urinary Tract Infections
- Cholecystitis, Acute
- Cholangitis Acute
- Intraabdominal Infections

## Interventions

- **DRUG:** Allocetra-OTS
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04612413
- **Lead sponsor:** Enlivex Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-12-16
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612413, "A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04612413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*